Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CGTX
CGTX logo

CGTX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Cognition Therapeutics Inc (CGTX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.080
1 Day change
0.93%
52 Week Range
3.830
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

CGTX is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is showing weak technical momentum, no fresh catalyst support, neutral insider and hedge fund activity, and no meaningful analyst or financial strength signals to justify an immediate long-term purchase. If you want exposure, waiting for a stronger trend reversal would be the better choice, but based on the current data this is not a buy-now setup.

Technical Analysis

The technical picture is bearish. MACD histogram is negative and still contracting, which points to weak momentum. RSI_6 at 45.8 is neutral and does not indicate a strong rebound setup. The moving averages are bearish with SMA_200 > SMA_20 > SMA_5, confirming the stock remains in a downtrend. Price at 1.175 is below the pivot level of 1.316, with support at 0.999 and resistance at 1.633. That means the stock is trading closer to lower support than breakout territory, but there is no confirmed reversal signal. The short-term pattern data suggests only limited upside probability and a negative expected move over the next month.

Positive Catalysts

  • Pre-market change was positive at 2.58%, regular session change was also positive at 3.54%, and post-market was slightly higher at 0.43%. This shows some near-term buying interest. The stock trend model also suggests a possible short-term bounce over the next day and next week.

Neutral/Negative Catalysts

  • No news in the recent week, so there are no event-driven catalysts. Hedge funds are neutral with no significant trading trend over the last quarter. Insiders are also neutral over the last month. AI Stock Picker shows no signal, and SwingMax shows no recent signal. Congress trading data is unavailable. The technical trend remains bearish, and the stock trend model projects negative performance over the next month.

Financial Performance

No usable financial snapshot was available due to a data error, so the latest quarter financial performance and growth trends cannot be assessed from the provided information.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there is no evidence of a recent upgrade cycle or target increase. Based on the available information, Wall Street appears undecided rather than strongly bullish, with no clear pros-side catalyst and no visible positive rating momentum.

Wall Street analysts forecast CGTX stock price to rise
2 Analyst Rating
Wall Street analysts forecast CGTX stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.070
sliders
Low
3
Averages
3
High
3
Current: 1.070
sliders
Low
3
Averages
3
High
3
B. Riley
B. Riley
Buy
maintain
$2 -> $3
AI Analysis
2025-11-21
Reason
B. Riley
B. Riley
Price Target
$2 -> $3
AI Analysis
2025-11-21
maintain
Buy
Reason
B. Riley raised the firm's price target on Cognition Therapeutics to $3 from $2 and keeps a Buy rating on the shares. Cognition's Phase 2 START trial for early Alzheimer's has fully enrolled 540 patients, reinforcing momentum from prior positive Phase 2b results and rising investigator interest in oral zervimesine, the analyst tells investors in a research note. With an 18-month primary endpoint and allowance for combination therapy, the trial design offers meaningful de-risking ahead of a mid-to-late 2027 readout, the firm adds.

People Also Watch